Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron [MG]) combined with a supplement (alpha-lipoic acid [ALA]) may help.
Objective:
To learn how MG and ALA can help the body process food.
Eligibility:
People aged 18 to 65 years with a body mass index between 30 and 40 kg/m2.
Design:
Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician.
The study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay.
During the clinic stays, participants will undergo many tests:
They will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin.
They will have imaging scans.
They will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe.
Participants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine.
They will log their diet, exercise, and sleep....

开始日期2025-06-02

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

NCT06803030

/ Not yet recruiting临床3期IIT

A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

开始日期2025-04-01

申办/合作机构

Bir Hospital

NCT06791460

/ Recruiting临床2/3期IIT

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial

The goal of this clinical trial is to learn if drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron. The main questions it aims to answer are:
Does drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron reduce tumor volume? What medical problems do participants have when taking drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron?
Researchers will compare drug regimen pegylated liposomal doxorubicin and adebrelimab with mirabegron to a drug regimen pegylated liposomal doxorubicin and adebrelimab without mirabegron to see which drug regimen works better to treat relapsed ovarian cancer.
Participants will:
Take drug pegylated liposomal doxorubicin and adebrelimab every 21 days with or without everyday mirabegron Visit the clinic once every 2 months for checkups and tests Keep a diary of their symptoms

开始日期2025-03-18

申办/合作机构

复旦大学附属妇产科医院

100 项与米拉贝隆相关的临床结果

登录后查看更多信息

100 项与米拉贝隆相关的转化医学

登录后查看更多信息

100 项与米拉贝隆相关的专利（医药）

登录后查看更多信息

1,572

项与米拉贝隆相关的文献（医药）

2025-05-05·MOLECULAR PHARMACEUTICS

Colon-Targeted β₃-Adrenoceptor Agonist Mirabegron Enhances Anticolitic Potency of the Drug via Potentiating the Nrf2-HO-1 Pathway

Article

作者: Yoon, In-Soo ; Yoo, Jin-Wook ; Kim, Jaejeong ; Kang, Changyu ; Jung, Yunjin

The selective agonist of β₃-adrenergic receptor mirabegron (MBG), clinically used to treat overactive bladders, exerts beneficial effects in animal models of colitis. Here, we aimed to enhance the therapeutic activity and safety of MBG as an anticolitic drug by implementing colon-targeted drug delivery using a prodrug approach. MBG was azo-linked with salicylic acid (SA) to yield SA-conjugated MBG (MAS), which was conjugated with aspartic acid (Asp) and glutamic acid (Glu) to yield more hydrophilic derivatives: Asp-conjugated MAS (MAS-Asp) and Glu-conjugated MAS (MAS-Glu). MBG derivatives reduced the distribution coefficient and cell permeability of MBG, which were greater with the amino acid-conjugated MAS than with MAS. MBG derivatives were cleaved to release MBG in the cecal contents. Upon oral gavage, compared with MBG, MBG derivatives delivered greater amounts of MBG to the cecum while limiting the systemic absorption of MBG, and the amino acid-conjugated MAS exhibited a greater performance than MAS. In a rat colitis model, MBG derivatives were more effective than MBG in ameliorating colonic damage and inflammation, and the amino acid-conjugated MAS was more potent than MAS. MAS-Glu was therapeutically superior to sulfasalazine, a current drug to treat inflammatory bowel disease, against rat colitis. Moreover, MBG activated the anti-inflammatory nuclear factor erythroid 2-related factor 2 (Nrf2)-hemeoxygenase (HO)-1 pathway in inflamed colonic tissue, and the MAS-Glu-mediated amelioration of colitis was significantly compromised by an HO-1 inhibitor. Taken together, colon-targeted delivery of MBG may enhance the anticolitic activity, reduce the risk of systemic side effects of MBG, and elicit the therapeutic effects, at least partly by activating the Nrf2-HO-1 pathway.

2025-05-01·Urogynecology (Philadelphia, Pa.)

Why Wasn't Mirabegron Chosen for the First Year of the CMS Negotiation Program?

Article

作者: Cadish, Lauren A. ; Shepherd, Jonathan P.

Importance:

The most used overactive bladder (OAB) medications are anticholinergics, which professional societies recommend avoiding in older patients given dementia risk. Cost prevents patients from switching to preferred beta-3 agonists. Mirabegron was the only beta-3 agonist eligible for the Centers for Medicare & Medicaid Services (CMS) 2023 Drug Negotiation Program (DNP). Although mirabegron's price would be markedly reduced by inclusion in the DNP, only 10 drugs were chosen in its first year.

Objectives:

We sought to explain mirabegron's absence from CMS's 2023 DNP and estimate the percentage of anticholinergic to mirabegron conversions needed to merit DNP inclusion.

Study Design:

We modeled CMS's 2023 selection process using publicly available dashboards from 2017 to 2021. Among the 20 costliest drugs, we excluded ineligible drugs and categorized the remainder as DNP chosen/not chosen. For drugs not chosen, we used price inflation and beneficiary utilization trends to project total 2023 costs.

Results:

In 2021, mirabegron was the 14th most costly drug overall—9th when excluding ineligibles—and the only top 20 drug eligible but not selected for the 2023 DNP. We estimated mirabegron to be 96.7% the cost of the 10th most costly drug. Switching 1.2% of 2021 anticholinergic prescriptions to mirabegron would have led to DNP inclusion, presenting an interesting dilemma where more patients would use mirabegron if it were cheaper, but insufficient patients used it for DNP inclusion to make it cheaper.

Conclusions:

Mirabegron came exceedingly close to DNP selection in 2023, and its future inclusion in the DNP would likely herald a massive shift of Medicare patients away from anticholinergics.

2025-05-01·UROLOGY

Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Review

作者: Liang, Pu ; Yu, Liqian ; Xia, Bowen ; Zhang, Dongxu

OBJECTIVE:

To compare the efficacy and safety of mirabegron and vibegron in female patients with overactive bladder (OAB).

METHODS:

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A meta-analysis of randomized controlled trials (RCTs) referred to the use of mirabegron and vibegron in female patients with OAB from PubMed, EMBASE, Cochrane Library, and Web of Science databases was performed.

RESULTS:

Three RCTs involving 371 patients were included. We found that vibegron was more effective in relieving urgency urinary incontinence in females with OAB compared to mirabegron [mean difference (MD)=0.25, 95% confidence interval (CI) 0.04 to 0.47, p=0.02]. And vibegron was similar to mirabegron in OAB symptom score (OABSS) [MD=0.22, 95% CI -0.32 to 0.76, p=0.42], urgency (MD=0.15, 95% CI -0.08 to 0.38, p=0.20), quality of life (QOL) (MD=-0.18, 95% CI -0.49 to 0.13, p=0.26), mean volume voided per micturition (MD=-6.16, 95% CI -21.50 to -9.17, p=0.43). In terms of the safety outcomes, there were no significant differences between mirabegron and control groups in terms of the total adverse events (TAEs) [odds ratio (OR)=0.75; 95% CI: 0.44 to 1.26; p=0.28], dry mouth (OR=1.01; 95% CI: 0.36 to 2.81; p=0.99), constipation (OR=0.69; 95% CI: 0.33 to 1.44; p=0.32), elevated post-void residual (PVR) (OR=0.35; 95% CI: 0.05 to 2.23; p=0.26), and dizziness (OR=1.02; 95% CI: 0.14 to 7.31; p=0.98).

CONCLUSION:

In female OAB patients, the efficacy and safety of mirabegron and vibegron were similar. Vibegron may be more effective than mirabegron in relieving urgency urinary incontinence.

127

项与米拉贝隆相关的新闻（医药）

2025-05-20

·Business Wire

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials. "Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials...the product launch adds to the company’s offerings of Epinephrine Injection." Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. The product launch adds to the company’s offerings of Epinephrine Injection. In December 2024, Fresenius Kabi introduced the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers. “We are pleased to offer our customers a cost-effective solution that supports quality patient care,” said Arun Verma, president, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. “At Fresenius Kabi, we are continually striving for new solutions as a trusted partner with the healthcare community.” Epinephrine Injection is manufactured in the U.S., reflecting the company’s commitment to domestic production. Since 2017, Fresenius Kabi has invested nearly $1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. More than 70% of the units shipped by Fresenius Kabi in the U.S. are drugs listed on the FDA’s Essential Medicines List. To learn more, visit our More in America page. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Do not inject into buttocks, digits, hands, or feet. Avoid extravasation into tissues, which can cause local necrosis. Monitor patient for acute severe hypertension. Potential for pulmonary edema, which may be fatal. May constrict renal blood vessels and decrease urine formation. May induce potentially serious cardiac arrhythmias or aggravate angina pectoris, particularly in patients with underlying heart disease. Presence of sulfite in this product should not deter use. ADVERSE REACTIONS Most common adverse reactions to systemically administered epinephrine are headache; anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; peripheral coldness; nausea/vomiting; and/or respiratory difficulties. Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, ergot alkaloids, and phenothiazine antipsychotics. Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin. Drugs that increase the arrhythmogenic potential of epinephrine include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides. Observe for development of cardiac arrhythmias. Potassium-depleting drugs, including corticosteroids, diuretics, and theophylline, potentiate the hypokalemic effects of epinephrine. USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally. INDICATIONS AND USAGE Epinephrine is a non-selective alpha- and beta-adrenergic agonist indicated: For emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients. To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. This Important Safety Information does not include all the information needed to use Epinephrine Injection, USP safely and effectively. Please see full prescribing information for Epinephrine Injection, USP. About Fresenius Kabi As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad global portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. For more information, please visit www.fresenius-kabi.com. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn and Facebook.

上市批准

2025-05-19

·药筛

药交会前瞻：最卷的100个药品

参加广州药交会，提前做好产品攻略！纯干货，无废话。这是系列四：2024年1月1日-2025年4月30日获批企业数量排名前100药品。排名药品名称持有人数量1地夸磷索钠滴眼液362间苯三酚注射液343乳果糖口服溶液304米诺地尔搽剂295二羟丙茶碱注射液276玻璃酸钠滴眼液267法莫替丁注射液268他达拉非片269硫酸氨基葡萄糖胶囊2510帕拉米韦注射液2311磷酸奥司他韦干混悬剂2212磷酸奥司他韦胶囊2213己酮可可碱注射液2114氨溴特罗口服溶液2015复方聚乙二醇电解质散(III)1916注射用尼可地尔1917达格列净片1718利丙双卡因乳膏1719罗沙司他胶囊1720吸入用乙酰半胱氨酸溶液1721恩格列净片1622盐酸乌拉地尔注射液1623阿戈美拉汀片1524富马酸福莫特罗吸入溶液1525硫酸镁钠钾口服用浓溶液1526注射用盐酸罗沙替丁醋酸酯1527磷酸西格列汀片1428马来酸阿伐曲泊帕片1429美索巴莫注射液1430盐酸多巴酚丁胺注射液1431吲哚布芬片1432注射用氯诺昔康1433甲钴胺片1334氯化钾颗粒1335氯化钾注射液1336马来酸氟伏沙明片1337普拉洛芬滴眼液1338沙库巴曲缬沙坦钠片1339腺苷钴胺胶囊1340盐酸奥洛他定滴眼液1341盐酸达泊西汀片1342注射用头孢唑肟钠1343二甲双胍恩格列净片(Ⅰ)1244富马酸伏诺拉生片1245盐酸艾司洛尔注射液1246盐酸多巴胺注射液1247盐酸莫西沙星滴眼液1248盐酸莫西沙星氯化钠注射液1249艾曲泊帕乙醇胺片1150普瑞巴林胶囊1151瑞巴派特片1152西格列汀二甲双胍片(Ⅱ)1153盐酸氨溴索口服溶液1154盐酸丙卡特罗口服溶液1155地氯雷他定口服溶液1056非布司他片1057硫酸镁注射液1058麦考酚钠肠溶片1059盐酸去氧肾上腺素注射液1060盐酸左沙丁胺醇雾化吸入溶液1061左氧氟沙星滴眼液1062阿加曲班注射液963枸橼酸西地那非口崩片964拉考沙胺注射液965莫匹罗星软膏966普瑞巴林口服溶液967氢溴酸伏硫西汀片968瑞戈非尼片969重酒石酸间羟胺注射液970重酒石酸去甲肾上腺素注射液971注射用头孢他啶阿维巴坦钠972左乙拉西坦口服溶液973阿司匹林肠溶片874布洛芬混悬液875地诺孕素片876多巴丝肼片877多索茶碱注射液878二甲双胍恩格列净片(Ⅵ)879甲硫酸新斯的明注射液880聚乙烯醇滴眼液881硫酸羟氯喹片882铝碳酸镁咀嚼片883米拉贝隆缓释片884舒更葡糖钠注射液885碳酸氢钠林格注射液886头孢地尼颗粒887吸入用硫酸沙丁胺醇溶液888硝酸异山梨酯注射液889熊去氧胆酸胶囊890溴芬酸钠滴眼液891依折麦布片892左卡尼汀口服溶液893艾司奥美拉唑镁肠溶胶囊794奥拉帕利片795奥美沙坦酯氨氯地平片796奥硝唑注射液797倍他米松磷酸钠注射液798吡拉西坦注射液799富马酸丙酚替诺福韦片7100钆特酸葡胺注射液7101枸橼酸托法替布片7102骨化三醇软胶囊7103甲磺酸雷沙吉兰片7104酒石酸溴莫尼定滴眼液7105聚乙二醇4000散7106利奈唑胺葡萄糖注射液7107硫酸沙丁胺醇注射液7108硫酸特布他林雾化吸入用溶液7109罗库溴铵注射液7110洛索洛芬钠凝胶贴膏7111氯化钾口服溶液7112他氟前列素滴眼液7113碳酸镧咀嚼片7114维格列汀片7115西甲硅油乳剂7116吸入用复方异丙托溴铵溶液7117吸入用盐酸丙卡特罗溶液7118缬沙坦氨氯地平片(Ⅰ)7119盐酸胺碘酮注射液7120盐酸氮卓斯汀滴眼液7121依帕司他片7122注射用厄他培南钠7123左卡尼汀注射液7124左西孟旦注射液7125左氧氟沙星氯化钠注射液7126左氧氟沙星片7（手工整理，如有错误或遗漏，欢迎补充）用摩熵药筛小程序，快速查询产品信息。

申请上市

2025-05-15

·PRNewswire

Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration

Endo's products are the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bag MALVERN, Pa., May 15, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of ADRENALIN® (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag and will begin shipping the product the week of May 19, 2025. ADRENALIN® is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag. "Hospital pharmacists and healthcare providers are working harder than ever, and we are committed to supporting them with ready-to-use medicines that help reduce complexity and streamline operations so they can focus on what matters most—patient care," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics. "With this new ADRENALIN® premixed bag concentration, plus the additional concentrations in our pipeline, we are proud to offer options and choice through our TruDelivery® portfolio." Key product benefits include: No compounding or preparation required Single-port IV tubing to reduce the risk of inadvertent mixture 24-month shelf life at room temperature The ADRENALIN® premixed bag is part of Endo Injectable Solutions' TruDelivery® product line and platform. Ready-to-use products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow, and reduce the chance for preparation error—all of which support quality patient care. In addition to the new 8 mg/250 mL bag, Endo offers ADRENALIN® 4 mg/250 mL premixed bag and plans to launch 5 mg/250 mL and 10 mg/250 mL concentrations. The company also offers ADRENALIN® (epinephrine injection, USP) 1 mL single-dose and 30 mL multi-dose vials. ADRENALIN® is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hypertension: Because individual response to epinephrine may vary significantly, monitor blood pressure frequently and titrate to avoid excessive increases in blood pressure. Patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may experience severe, prolonged hypertension when given epinephrine. Pulmonary Edema: Epinephrine increases cardiac output and causes peripheral vasoconstriction, which may result in pulmonary edema. Cardiac Arrhythmias and Ischemia: Epinephrine may induce cardiac arrhythmias and myocardial ischemia in patients, especially patients suffering from coronary artery disease, or cardiomyopathy. Extravasation and Tissue Necrosis with Intravenous Infusion: Avoid extravasation of epinephrine into the tissues, to prevent local necrosis. When Adrenalin is administered intravenously, check the infusion site frequently for free flow. Blanching along the course of the infused vein, sometimes without obvious extravasation, may be attributed to vasa vasorum constriction with increased permeability of the vein wall, permitting some leakage. This also may progress on rare occasions to superficial slough. Hence, if blanching occurs, consider changing the infusion site at intervals to allow the effects of local vasoconstriction to subside. There is potential for gangrene in a lower extremity when infusions of catecholamine are given in an ankle vein. Antidote for Extravasation Ischemia: To prevent sloughing and necrosis in areas in which extravasation has taken place, infiltrate the area with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of phentolamine, an adrenergic blocking agent. Use a syringe with a fine hypodermic needle, with the solution being infiltrated liberally throughout the area, which is easily identified by its cold, hard, and pallid appearance. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. Renal Impairment: Epinephrine constricts renal blood vessels, which may result in oliguria or renal impairment. ADVERSE REACTIONS: Most common adverse reactions to systemically administered epinephrine are headache; anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; peripheral coldness; nausea/vomiting; and/or respiratory difficulties. Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred. DRUG INTERACTIONS: Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, catechol-O-methyltransferase (COMT) inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. Drugs that increase the arrhythmogenic potential of epinephrine include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, antihistamines, exogenous thyroid hormones, diuretics, cardiac glycosides, and quinidine. Observe for development of cardiac arrhythmias. Potassium-depleting drugs, including corticosteroids, diuretics, and theophylline, potentiate the hypokalemic effects of epinephrine. USE IN SPECIFIC POPULATIONS: Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally. Click for Full Prescribing Information. About Endo Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Mr. Sims and any statements relating to product shipments, commercial availability, product benefits, reduction of waste, costs and errors, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, regulatory compliance, unexpected litigation or disputes, Endo's ability to successfully implement and execute on its strategies and initiatives, and changes in competitive, market or regulatory conditions. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-K and Form 10-Q. SOURCE Endo, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

100 项与米拉贝隆相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09535	米拉贝隆	G04BD12	DB08893

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
神经源性逼尿肌过度活动	欧盟	Astellas Pharma Europe Ltd.	2024-09-05
神经源性逼尿肌过度活动	冰岛	Astellas Pharma Europe Ltd.	2024-09-05
神经源性逼尿肌过度活动	列支敦士登	Astellas Pharma Europe Ltd.	2024-09-05
神经源性逼尿肌过度活动	挪威	Astellas Pharma Europe Ltd.	2024-09-05
膀胱过度活动症综合征	欧盟	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症综合征	冰岛	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症综合征	列支敦士登	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症综合征	挪威	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症	日本	Astellas Pharma, Inc.	2011-07-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间质性膀胱炎	临床3期	美国	Astellas Pharma Global Development, Inc.	2016-08-01
尿失禁	临床3期	美国	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	亚美尼亚	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	澳大利亚	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	奥地利	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	比利时	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	加拿大	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	捷克	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	丹麦	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	芬兰	Astellas Pharma Europe Ltd.	2013-07-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MIRAQL-BAT STUDY (EANM2024)	N/A	-	20	Mirabegron 100 mg/day + Placebo	壓遞積壓鹹鬱構淵鹽鏇(衊鏇餘鑰願築窪壓餘齋) = 網餘築艱顧壓壓簾鹹築範願膚夢蓋觸餘範糧鹹 (繭鏇廠範壓構觸蓋襯壓 ) 更多	积极	2024-09-27
				Mirabegron 200 mg/day + Placebo	壓遞積壓鹹鬱構淵鹽鏇(衊鏇餘鑰願築窪壓餘齋) = 齋鬱觸廠鏇壓齋鹽艱簾範願膚夢蓋觸餘範糧鹹 (繭鏇廠範壓構觸蓋襯壓 ) 更多
NCT04766021 (CTgov)	临床1/2期	-	30	Placebo (Placebo)	憲膚繭構夢餘夢窪網願(齋範醖衊壓範廠壓簾鹹) = 鑰選鏇簾顧糧蓋憲鬱鬱襯願鏇構觸餘餘繭製鬱 (鹽窪鑰鹽積齋齋夢顧鏇, 67.8) 更多	-	2024-07-12
				Mirabegron (100 mg Mirabegron)	憲膚繭構夢餘夢窪網願(齋範醖衊壓範廠壓簾鹹) = 願鑰遞鹹鬱積醖鹹淵衊襯願鏇構觸餘餘繭製鬱 (鹽窪鑰鹽積齋齋夢顧鏇, 75.7) 更多
PD07-09 (AUA2024)	N/A	-	-	Mirabegron	願簾構獵窪觸淵鏇範膚(獵艱網製糧獵餘鑰齋鑰) = 範鏇艱醖築獵築鏇顧醖鏇鹽製築窪蓋憲積夢獵 (襯糧膚選餘鹽蓋顧窪繭 )	积极	2024-05-01
				Anticholinergics	願簾構獵窪觸淵鏇範膚(獵艱網製糧獵餘鑰齋鑰) = 鏇窪蓋廠製鹹膚構糧餘鏇鹽製築窪蓋憲積夢獵 (襯糧膚選餘鹽蓋顧窪繭 )
NCT01876433 (Pubmed \| J Cardiovasc Pharmacol) 人工标引	临床2期	射血分数降低的心力衰竭	57	Mirabegron (300 mg/day)	夢窪壓齋壓願膚網艱糧(選製鹽願廠齋範鏇襯鏇) = Baseline and follow-up data: placebo: 13 ± 7 to 13 ± 5; mirabegron: 12 ± 6 to 13 ± 8 積鏇廠鏇膚製築製壓窪 (窪窪選壓選鑰選築積鏇 ) 更多	积极	2024-03-05
				Placebo
NCT04641975 (Dolphin, CTgov)	临床3期	膀胱过度活动症	26	Mirabegron (Mirabegron (5 to < 12 Years))	獵淵襯積壓壓壓鹹鬱齋(蓋艱憲積範顧顧遞襯膚) = 築糧遞壓遞顧膚鑰醖選製蓋糧衊夢憲遞壓獵構 (壓選築鹹餘簾鬱餘遞壓, 0.89) 更多	-	2023-12-28
				Placebo (Placebo (5 to < 12 Years))	獵淵襯積壓壓壓鹹鬱齋(蓋艱憲積範顧顧遞襯膚) = 廠鑰網積襯鹽顧繭衊積製蓋糧衊夢憲遞壓獵構 (壓選築鹹餘簾鬱餘遞壓, 0.89) 更多
NCT02599480 (Beta3-LVH, Pubmed \| JAMA Cardiol)	临床2期	心脏病	296	Mirabegron 50 mg/d	憲範衊齋選憲網艱製獵(糧繭鹽網糧顧憲窪鏇繭) = 齋壓夢獵鬱網窪觸觸選顧顧積壓顧願餘鬱顧襯 (壓製襯膚艱顧憲鹽積壓, -0.15 ~ 2.74)	不佳	2023-11-01
NCT02086188 (MIRROR, CTgov)	临床4期	多发性硬化症 \| 膀胱过度活动症	28	Mirabegron (Mirabegron)	壓蓋齋觸憲醖齋鹹餘鬱(觸構壓網選膚鏇襯選廠) = 觸窪夢製顧簾選遞鑰衊膚構願衊顧範選衊齋遞 (繭顧廠網窪糧觸獵夢繭, 0.48) 更多	-	2023-10-18
				Placebo (Placebo)	壓蓋齋觸憲醖齋鹹餘鬱(觸構壓網選膚鏇襯選廠) = 鹹齋構觸願齋製製淵醖膚構願衊顧範選衊齋遞 (繭顧廠網窪糧觸獵夢繭, 0.84) 更多
NCT04907032 (PTNS-M, CTgov)	临床4期	膀胱过度活动症	54	Posterior Tibial Nerve Stimulation (PTNS)+Mirabegron 50 MG (Posterior Tibial Nerve Stimulation With Mirabegron)	憲積夢糧鹽選範艱襯衊(鑰壓餘鬱膚夢廠選夢獵) = 膚齋壓鹹製蓋夢夢膚觸鬱醖範糧壓顧繭簾襯鹽 (鬱製繭淵繭膚壓襯鑰鏇, 3.9) 更多	-	2023-07-20
				Posterior Tibial Nerve Stimulation (PTNS) (Posterior Tibial Nerve Stimulation Plus Placebo)	憲積夢糧鹽選範艱襯衊(鑰壓餘鬱膚夢廠選夢獵) = 築夢壓觸顧膚選餘糧顧鬱醖範糧壓顧繭簾襯鹽 (鬱製繭淵繭膚壓襯鑰鏇, 5.4) 更多
NCT02462837 (CTgov)	临床2期	疼痛 \| 下尿路症状 \| 膀胱过度活动症	11	Mirabegron (Treatment Arm)	鏇齋構廠鹹齋簾膚觸願(淵齋艱醖網選顧壓膚鹹) = 獵積簾鬱蓋鏇餘齋壓夢衊鏇鬱鹽網顧獵願壓艱 (鑰鏇選襯築醖襯淵醖繭, 壓淵襯憲衊襯獵範簾餘 ~ 餘觸鹹積築糧鬱窪窪願) 更多	-	2023-06-13
				Placebo (Placebo Arm)	鏇齋構廠鹹齋簾膚觸願(淵齋艱醖網選顧壓膚鹹) = 構廠窪獵艱醖繭壓願壓衊鏇鬱鹽網顧獵願壓艱 (鑰鏇選襯築醖襯淵醖繭, 襯壓鹹構築鏇衊鏇蓋繭 ~ 觸艱構鏇築衊襯窪蓋構) 更多
PD14-07 (AUA2023)	N/A	-	-	Mirabegron	鑰遞鹹蓋獵膚築齋廠鹽(憲鑰壓積遞憲選鏇糧簾) = 繭醖範鑰簾遞壓構鑰衊鏇範襯膚顧構齋襯憲鹹 (憲積蓋鑰蓋艱製築艱遞 ) 更多	-	2023-04-01